| At IPF diagnosis |
| Systematic |
| Chest HRCT |
| FVC and DLCO |
| Doppler echocardiography |
| Biology |
| Antinuclear antibodies |
| Anti-citrullinated cyclic peptides antibodies |
| Rheumatoid factor |
| Differential blood cell count |
| C-reactive protein |
| Serum creatinine |
| Transaminases, γ-glutamyltransferase and alkaline phosphatases |
| Occasional |
| Video-assisted surgical lung biopsy (see text) |
| Differential cell count of BAL (see text) |
| TLC and arterial blood gas in room air at rest |
| 6MWT with measurement of percutaneous oxygen saturation |
| Depending on context |
| Genetic testing (see text) |
| Anti-neutrophil cytoplasmic antibodies |
| Anti-SSA and anti-SSB antibodies |
| Anti-centromere and anti-topoisomerase antibodies |
| Anti-Mi-2, anti-U3RNP and anti-ARNt synthetase antibodies |
| Creatine phosphokinase |
| Anti-thyroid antibodies |
| Precipitines (depending on disease presentation) |
| Microbiology of BAL |
| Electrophoresis of serum proteins, immuno-electrophoresis of serum proteins, urine immunofixation and cryoglobulinaemia |
| Exploration for gastro-oesophageal reflux |
| Exploration for sleep apnoea syndrome |
| During follow-up |
| Every 3 to 6 months |
| FVC and DLCO |
| Depending on context |
| Chest HRCT |
| Doppler echocardiography |
| TLC |
| Arterial blood gas in room air |
| Right heart catheterisation (see text) |
HRCT: high-resolution computed tomography; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; BAL: bronchoalveolar lavage; TLC: total lung capacity; 6MWT: 6-min walk test.